GlassScriptPhysician profile
Shachar Tauber
NPI 1174689723
$150,319.87
in general payments reported to CMS, 2019-2025
30 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $33K · 2021: $28K · 2022: $19K · 2023: $9,562 · 2024: $9,934 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Food and Beverage: $6,934 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,950 · Travel and Lodging: $1,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,963.75 |
| Food and Beverage | $6,933.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,950.00 |
| Travel and Lodging | $1,417.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $77,424.42 | 2019-2025 | Baerveldt Glaucoma Implant (250), Compact Intuitiv, Whitestar Phaco Handpiece |
| Sun Pharmaceutical Industries INC. | $35,853.95 | 2019-2025 | Cequa |
| Glaukos Corporation | $18,982.43 | 2019-2025 | Epioxa, Ce-Marked Kxla System, Travoprost Intraocular Implant - Idose |
| Shire North American Group INC | $8,104.70 | 2019 | |
| Apellis Pharmaceuticals, INC. | $1,632.50 | 2025 | Syfovre |
| Dompe US, INC. | $1,371.13 | 2019-2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $1,300.00 | 2021 | |
| Aerie Pharmaceuticals, INC. | $709.67 | 2019 | |
| Rxsight INC | $688.84 | 2021-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Carl Zeiss Meditec, INC. | $674.73 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $604.52 | 2021-2023 | |
| Allergan, INC. | $499.90 | 2019-2021 | |
| Harrow Eye, LLC | $374.78 | 2024-2025 | Vevye, Flarex |
| Novartis Pharmaceuticals Corporation | $300.81 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $255.24 | 2022-2025 | Xiidra, Miebo, Lotemax Sm |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $250.80 | 2022-2023 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $171.44 | 2024 | Tecnis Simplicity |
| Sight Sciences, INC. | $145.89 | 2019 | |
| Lensar, INC. | $140.37 | 2022 | |
| Genmab U.S., INC. | $124.84 | 2022 | |
| Staar Surgical Company | $119.95 | 2019 | |
| Alcon Vision LLC | $117.91 | 2022 | |
| Eyevance Pharmaceuticals LLC | $114.57 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.85 | 2021 | |
| Abbvie INC. | $96.53 | 2022 | |
| Biosense Webster, INC. | $63.54 | 2019 | |
| Ocular Therapeutix, INC. | $59.29 | 2019 | |
| Tearlab Corp | $23.76 | 2024 | Scoutpro Osmolarity System |
| Biotissue Holdings INC. | $13.51 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$100,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shachar Tauber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.